Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Synchroneuron Raises $20M in Series B Funding

Published: Wednesday, July 02, 2014
Last Updated: Tuesday, July 08, 2014
Bookmark and Share
Funding supports continued development of SNC-102, a new formulation of acamprosate calcium currently being studied in a Phase 2 trial to treat moderate-to-severe tardive dyskinesia.

Synchroneuron today announced the closing of a $20 million Series B funding round from sole-investor Morningside Technology Ventures Limited. 

“Morningside’s investment in Synchroneuron demonstrates our belief in the potential of SNC-102 to safely and effectively treat neuropsychiatric disorders such as tardive dyskinesia as well as its potential in additional indications,” said Gerald Chan, Chairman of Morningside Technology Ventures. 

Top-line data from Synchroneuron’s Phase 2, multi-center, randomized, double-blind, placebo-controlled trial of SNC-102 is expected early in 2015. Approximately half of the subjects have entered or already completed the study. In addition, Synchroneuron expects to begin open label studies of SNC-102 in Tourette syndrome and post-traumatic stress syndrome (PTSD) to prove the concept of the drug’s broader efficacy for neuropsychiatric disorders potentially related to glutamate/GABA imbalance. 

“SNC-102 has the potential to be the first FDA-approved drug for tardive dyskinesia, a debilitating and often irreversible movement disorder,” said William Kerns, DVM, Chief Executive Officer of Synchroneuron Inc. “In addition, SNC-102’s distinct mechanism of action, which modulates activity of glutamate without producing the toxicity associated with NMDA antagonists or benzodiazepine-like drugs, may translate into a treatment option for patients with Tourette syndrome and PTSD.” 

Funds from the Series B will support the Company’s active formulation improvement program, additional open label studies of SNC-102 and preclinical studies to better understand acamprosate’s pharmacokinetics and mechanism of action through the end of 2016.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Developing Novel Ear Infection Treatments
Research team engineers antibiotic gel for treating middle ear infections.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Arms Race with a Superbug
Scientists have discovered that increased risk of superbug infection can be directly casued by immune system response to invading bacteria.
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!